4.5 Review

The SIX1-EYA transcriptional complex as a therapeutic target in cancer

Journal

EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 19, Issue 2, Pages 213-225

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.2014.978860

Keywords

inhibition of transcriptional complexes; metastasis; phosphatase; protein-protein interaction; six1/eyes absent complex; transcription factor

Funding

  1. Department of Defense Breast Cancer Program
  2. Ovarian Cancer Program
  3. Breast Cancer Research Foundation-American Association for Cancer Research
  4. State of Colorado
  5. Cancer League of Colorado
  6. Alex's Lemonade Stand Foundation
  7. V Foundation for Cancer Research
  8. Sidney Kimmel Foundation
  9. National Institute of Health [R03DA030559, R03DA033174, R41CA180347]
  10. National Cancer Institute [R01CA095277, R01CA157790]
  11. Paul Sandoval Pancreatic Cancer Scholarship
  12. UNCF/MERCK Graduate Fellowship
  13. R01 Diversity supplement
  14. Pediatric Hematology/Oncology Postdoctoral Fellowship [2T32082086-11A1]

Ask authors/readers for more resources

Introduction: The SIX homeodomain proteins and the eyes absent (EYA) family of co-activators form a bipartite transcription factor complex that promotes the proliferation and survival of progenitor cells during organogenesis and is down-regulated in most adult tissues. Abnormal overexpression of SIX1 and EYA in adult tissue is associated with the initiation and progression of diverse tumor types. Importantly, SIX1 and EYA are often co-overexpressed in tumors, and the SIX1-EYA2 interaction has been shown to be critical for metastasis in a breast cancer model. The EYA proteins also contain protein tyrosine phosphatase activity, which plays an important role in breast cancer growth and metastasis as well as directing cells to the repair pathway upon DNA damage. Areas covered: This review provides a summary of the SIX1/EYA complex as it relates to development and disease and the current efforts to therapeutically target this complex. Expert opinion: Recently, there have been an increasing number of studies suggesting that targeting the SIX1/EYA transcriptional complex will potently inhibit tumor progression. Although current attempts to develop inhibitors targeting this complex are still in the early stages, continued efforts toward developing better compounds may ultimately result in effective anti-cancer therapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available